Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Adds Smart Insulin Pen By Acquiring Companion Medical

Executive Summary

The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery. 

You may also be interested in...



Medtronic Adds Avenu’s Percutaneous Fistula Technology

Avenu’s Ellipsys vascular access system is an ultrasound-guided catheter to create a durable arteriovenous fistula for patients undergoing dialysis.

Insulin Pump Market Heats Up Among Rivals Medtronic, Insulet and Tandem

Three major insulin pump developers are gearing up to introduce next-generation devices over the coming year, but COVID-19 continues to create uncertainties.

ADA 2020: Medtronic Explains Strategy To Return Growth To Diabetes Business

Medtronic will launch its next-generation MiniMed 780G insulin pump while continuing to develop complementary technologies to close the competitive gap with its rivals in the diabetes market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel